X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE PANACEA BIOTECH TTK HEALTHCARE/
PANACEA BIOTECH
 
P/E (TTM) x 21.7 -20.0 - View Chart
P/BV x 7.3 2.8 259.4% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 TTK HEALTHCARE   PANACEA BIOTECH
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
PANACEA BIOTECH
Mar-14
TTK HEALTHCARE/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs663149 446.1%   
Low Rs39982 484.8%   
Sales per share (Unadj.) Rs535.684.1 636.6%  
Earnings per share (Unadj.) Rs15.9-18.3 -87.1%  
Cash flow per share (Unadj.) Rs20.0-6.7 -298.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs137.683.7 164.4%  
Shares outstanding (eoy) m7.7761.25 12.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.01.4 72.2%   
Avg P/E ratio x33.3-6.3 -528.0%  
P/CF ratio (eoy) x26.5-17.2 -153.8%  
Price / Book Value ratio x3.91.4 279.8%  
Dividend payout %25.10-   
Avg Mkt Cap Rs m4,1277,074 58.3%   
No. of employees `0001.72.8 62.1%   
Total wages/salary Rs m6071,449 41.9%   
Avg. sales/employee Rs Th2,436.71,874.1 130.0%   
Avg. wages/employee Rs Th355.2527.0 67.4%   
Avg. net profit/employee Rs Th72.5-407.7 -17.8%   
INCOME DATA
Net Sales Rs m4,1625,154 80.8%  
Other income Rs m61100 61.3%   
Total revenues Rs m4,2235,254 80.4%   
Gross profit Rs m197-766 -25.7%  
Depreciation Rs m32711 4.5%   
Interest Rs m301,503 2.0%   
Profit before tax Rs m197-2,881 -6.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m7317 433.3%   
Profit after tax Rs m124-1,121 -11.0%  
Gross profit margin %4.7-14.9 -31.9%  
Effective tax rate %37.0-0.6 -6,345.8%   
Net profit margin %3.0-21.8 -13.7%  
BALANCE SHEET DATA
Current assets Rs m1,6293,810 42.7%   
Current liabilities Rs m1,0588,365 12.6%   
Net working cap to sales %13.7-88.4 -15.5%  
Current ratio x1.50.5 338.0%  
Inventory Days Days30156 19.1%  
Debtors Days Days3467 50.0%  
Net fixed assets Rs m55614,480 3.8%   
Share capital Rs m7861 126.8%   
"Free" reserves Rs m878903 97.3%   
Net worth Rs m1,0695,127 20.9%   
Long term debt Rs m1595,832 2.7%   
Total assets Rs m2,39919,433 12.3%  
Interest coverage x7.6-0.9 -826.9%   
Debt to equity ratio x0.11.1 13.0%  
Sales to assets ratio x1.70.3 654.0%   
Return on assets %6.42.0 326.3%  
Return on equity %11.6-21.9 -53.0%  
Return on capital %18.53.6 507.5%  
Exports to sales %0.824.5 3.2%   
Imports to sales %1.410.2 13.8%   
Exports (fob) Rs m331,264 2.6%   
Imports (cif) Rs m58525 11.1%   
Fx inflow Rs m331,539 2.1%   
Fx outflow Rs m63942 6.7%   
Net fx Rs m-30597 -5.1%   
CASH FLOW
From Operations Rs m127599 21.1%  
From Investments Rs m-146-438 33.3%  
From Financial Activity Rs m22-303 -7.2%  
Net Cashflow Rs m3-141 -1.8%  

Share Holding

Indian Promoters % 65.4 74.5 87.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.6 616.7%  
FIIs % 5.2 1.3 400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 23.6 109.3%  
Shareholders   12,723 10,259 124.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   CADILA HEALTHCARE  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare TTK HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Aug 14, 2018 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE 8-QTR ANALYSIS

COMPARE TTK HEALTHCARE WITH

MARKET STATS